Intron Bio's new drug division announced on the 21st that it has confirmed the antioxidant efficacy of 'iN-SIS5', a new material that replaces Botox, in addition to its skin wrinkle improvement effects.
iN-SIS5, being developed as a substitute for Botox (botulinum neurotoxin), has been confirmed to fundamentally provide skin wrinkle improvement effects as a new material. Recently, iN-SIS5 was registered as an international cosmetic ingredient (ICID) and as a domestic cosmetic ingredient, drawing attention for its Botox-like efficacy. Major efficacy evaluation tests are being conducted to investigate its characteristics applicable to the cosmetic field. It was confirmed that iN-SIS5 also exhibits antioxidant efficacy.
In vivo, free radicals including reactive oxygen species and reactive nitrogen species are generated due to metabolic and external environmental factors. The antioxidant efficacy, which inhibits or reduces the oxidation of skin components that accelerate skin aging caused by these free radicals, is an important factor in cosmetic raw materials and finished products.
The antioxidant efficacy of iN-SIS5 was confirmed through the DPPH assay (2,2-diphenyl-1-picrylhydrazyl) test. Ji-Sung Park, head of Intron Bio, explained, "The efficacy is gradually being revealed in various ways," adding, "In addition to skin wrinkle improvement effects, antioxidant efficacy is an additional effect that iN-SIS5 can provide."
Intron Bio is promoting the business of iN-SIS5 in two major directions. The first is developing iN-SIS5 as a new drug, with a strategy to collaborate with related pharmaceutical and bio companies to create a medicine that can replace Botox. The second is expanding the application range of iN-SIS5 as a cosmetic raw material, proceeding with phased commercialization with related cosmetic companies.
Among the two-track strategy, Intron Bio is prioritizing commercialization related to cosmetics. It is strengthening cooperation by expanding strategic equity investment in Nod Mason, which owns the Huxley brand. It also made a strategic investment to secure the position of the second largest shareholder in Dermaject. Joint research is also being conducted to utilize microneedle technology for delivering the efficacy of not only iN-SIS5 but also pharmaceuticals.
Kyung-Won Yoon, CEO of Intron Bio, said, "iN-SIS5 is expected to provide not only the basic efficacy that Botox can offer but also multiple additional efficacies," adding, "We will gradually verify these further." He continued, "We are establishing a mass production system crucial for commercialization," and added, "We plan to proceed with full-scale mass production, productization, and marketing."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
